The pitch has gone well. The investor understands the market, likes the product, and wants another meeting. Then the conversation turns to the founder: How do you manage pressure? Can you lead a growing team? Are you reliable when the work becomes repetitive?
For an entrepreneur with ADHD or an autistic founder, these may be ordinary questions carrying an extraordinary private calculation. Should I explain how my mind works? Will it make the investor understand me—or make them doubt me? Am I withholding something important if I say nothing?
The dilemma is often presented as a test of courage: disclose proudly or hide in shame. That is a poor framing. A founder’s medical information is personal. An investor’s legitimate interest is the company’s capacity to execute and the truthfulness of its representations. Those interests may intersect, but they are not identical.
The better question is not simply whether to disclose. It is what information the investor actually needs, what the founder wants to share, and what kind of relationship the investment would create.
A Funding Room Is Not a Neutral Room
Fundraising prizes a peculiar performance: the founder must be unusually ambitious but reassuringly predictable; visionary yet operationally disciplined; different enough to see an opportunity yet familiar enough to be trusted with capital.
The tension is especially sharp when a founder communicates differently. An autistic entrepreneur who avoids prolonged eye contact may be perceived as evasive. A founder with ADHD who moves rapidly between ideas may be read as brilliant or scattered. Neither interpretation establishes what the person can actually build. These are examples of possible bias, not reliable diagnostic signs.
There is evidence that the dilemma is real, although the evidence should not be flattened into a universal statistic. In a 2024 report, the UK-based Entrepreneurs Network, working with Barclays Eagle Labs, reported that 78% of the 502 diagnosed neurodivergent founders surveyed had deliberately hidden their neurodivergence in business situations. Almost half reported facing discrimination regularly or always. The survey was conducted between December 29, 2023, and January 9, 2024. It records experiences in a defined UK sample; it does not establish the same prevalence among US venture-backed founders or prove that every investor discriminates.
That distinction matters. A founder should neither assume every investor is hostile nor pretend that the possibility of stigma is imaginary. Both naivety and cynicism can be expensive.
A 2025 paper by Lauren C. Howe and Jochen I. Menges, published in Organizational Behavior and Human Decision Processes, examined how entrepreneurs' disclosures of personal flaws influenced investors. Its findings depended on the type of disclosed flaw and perceived similarity. The study was not an experiment on founders disclosing ADHD or autism. It cannot tell an individual founder whether diagnosis disclosure will increase or decrease funding. It does, however, challenge the fashionable advice that greater vulnerability automatically produces greater trust.
Separate Three Kinds of Information
The disclosure problem becomes clearer when three different forms of information are no longer confused.
1. A diagnosis
ADHD and autism can be clinically significant, but a label alone does not describe someone's judgment, financial discipline, communication preferences or ability to lead. Autistic people and people with ADHD differ enormously from one another, and the two conditions can also co-occur. A diagnosis is not a substitute for a business assessment.
2. A working preference or support need
A founder might perform best with written questions before a meeting, a clear agenda, a brief pause to process complex financial questions, or a shared decision log. These preferences can often be communicated without naming a condition. They should be presented as ways to improve the accuracy and quality of the discussion—not as requests for indulgence.
3. A material business fact
Investors are entitled to accurate information about the venture: its cash position, liabilities, key-person dependencies, governance, regulatory exposure, forecast assumptions, and operational risks. If the business depends entirely on one person and has no continuity plan, the dependency is relevant regardless of that person's neurology. If the company has missed contractual commitments, those facts cannot be disguised by a positive narrative about strengths.
This distinction is the hinge of a responsible answer: privacy about a diagnosis must not become a pretext for misleading someone about the company. Equally, transparency about the company should not be converted into an indiscriminate demand for medical biography.
What US Law Does—and Does Not—Say
For a US fundraising context, two separate legal frameworks are frequently blurred.
The Americans with Disabilities Act contains important protections concerning disability-related questions and medical information in covered employment relationships. The Equal Employment Opportunity Commission explains, for example, that employers generally cannot ask applicants about the nature or severity of a disability before an employment offer. But an equity investor evaluating a venture is not automatically acting as an employer. It would be misleading to quote an employee's right to privacy as proof that every investor inquiry is unlawful.
Fundraising also implicates securities law. The US Securities and Exchange Commission's guidance on exempt offerings makes clear that federal antifraud provisions apply even when a securities transaction is exempt from registration. False or misleading company or offering statements can create liability. That is not the same thing as a general rule requiring every founder to volunteer ADHD or autism.
The practical rule is to distinguish the person's private medical status from representations that are materially relevant to the offering. The boundary can depend on the transaction, the founder's role, what investors have asked, contractual representations, and the actual facts. A founder negotiating a significant round should ask qualified US securities counsel to review difficult disclosure questions rather than rely on an article, a pitch coach, or a generic online template.
In other jurisdictions the legal balance may differ. This article addresses US-oriented startup fundraising; the cited UK founder survey describes experiences rather than governing US law.
Four Disclosure Strategies—Not Two
The supposed choice between complete secrecy and complete openness hides a spectrum of legitimate approaches.
| Approach | What it communicates | Potential advantage | Potential cost |
|---|---|---|---|
| Keep diagnosis private | Evidence about the company, with no medical information | Protects privacy and keeps attention on execution | May leave recurring misunderstandings unexplained |
| Share working preferences | “Written questions and a decision summary help me give precise answers” | Improves meeting conditions without clinical details | Some investors may still misread the request |
| Selective disclosure | Share a diagnosis with a particular investor when it serves a defined purpose | Can enable a candid, durable working relationship | Personal information may spread or shape perceptions |
| Open public disclosure | Make neurodivergence part of a founder's public story | Can attract aligned investors and customers, and reduce ongoing masking | Hard to reverse; may invite stereotyping and unwanted scrutiny |
None is universally superior. More disclosure is not necessarily more honest; less disclosure is not necessarily less authentic. The relevant variables are trust, need, consequences, timing, and control over onward sharing.
A disclosure is also not a one-time vote on identity. A founder might speak publicly about neurodiversity but keep medical details private. Another might disclose to a lead investor after weeks of trust-building but not to everyone in an initial pitch room. Both can be coherent choices.
What the Investor Actually Needs to Know
Suppose a founder is exceptionally good at customer discovery, product design and making strategic connections, but routinely loses track of meeting follow-ups. The investor's legitimate question is whether follow-up is reliable. The most convincing answer may be a shared CRM, a documented owner for each commitment, a chief of staff, and an operating cadence that shows completed actions.
The investor does not need to know a founder's entire medical history to inspect the evidence.
The same principle applies elsewhere. If financial reporting has been inconsistent, show the reconciled statements, finance support and a regular board-reporting schedule. If the founder is prone to impulsive pivots, demonstrate decision gates and a process for testing hypotheses. If a noisy, unpredictable meeting undermines communication, propose a written agenda and a short follow-up document.
These are not tricks to conceal weakness. They are a more mature way of answering the question: What makes this company dependable?
In a 2025 essay about neurodivergent founders and fundraising, investor and former founder Candice Matthews Brackeen argued from experience that founders should help investors understand how their distinctive approach translates into business value. This is a perspective from practice, not experimental proof. Its useful premise is that difference becomes relevant to investment when connected to decisions, systems and outcomes.
The Strongest Case for Disclosing
There are circumstances in which selective or public disclosure may be sensible.
First, some businesses exist precisely because the founder understands an underserved neurodivergent community. The founder's experience may be integral to the product insight, research agenda or community trust. Sharing relevant lived experience can explain why the venture exists without turning a diagnosis into its sole qualification.
Second, a funding relationship can last years. An investor who will sit on the board, demand repeated meetings, or influence hiring can materially shape the founder's working life. If a founder would need to mask continuously to maintain that relationship, early candid discussion may reveal a mismatch before it becomes costly.
Third, disclosure can support specific communication arrangements. A founder might say: “I have ADHD. I do my best strategic thinking when I can review financial questions in writing first. We have a finance lead who checks the numbers, and I will send you the decision record after the call.” The value lies in the combination of relevant context and operational evidence.
Finally, disclosure may be an expression of agency. Some founders decide that they no longer wish to treat a fundamental part of their experience as unspeakable. That is a legitimate choice even if it does not maximize the statistical probability of raising capital.
The strongest argument for disclosure, then, is not that investors deserve the diagnosis. It is that the founder may benefit from a relationship in which it can be spoken about openly.
The Strongest Case for Not Disclosing
Privacy is not a moral failure. Nor is every investor a safe audience.
A diagnosis is sensitive information that can outlive the fundraising process. It may travel through introductions, internal investment notes, diligence records, co-investor conversations or an investor's memory. Founders should not assume that a friendly verbal exchange creates legal confidentiality.
There is also a storytelling trap. Once a founder supplies a diagnostic label, an investor may reinterpret every ordinary startup difficulty through it: a delayed email becomes “ADHD”; a direct answer becomes “autism”; a strategic disagreement becomes “inflexibility.” The label may overwhelm the business facts instead of clarifying them.
The issue is particularly acute when someone is newly diagnosed, uncertain about terminology, or still deciding how much of that experience they want to make public. They need not turn unfinished personal understanding into pitch-deck material.
Some founders will therefore prefer a competence-first approach: demonstrate the actual systems, explain how the team manages risk, and preserve personal medical information unless a concrete reason for disclosure emerges. That approach can be fully compatible with truthful fundraising.
How to Ask for a Better Pitch Process Without Explaining Your Brain
Neurodivergent-friendly pitch design is often simply better pitch design.
Consider three changes that make an investor meeting more informative:
Before: send the deck, metrics, agenda and key assumptions so questions can address the real investment thesis.
During: distinguish questions requiring an immediate view from those requiring verified numbers; allow a moment for written notes or a clarification.
After: issue a concise follow-up with the requested documents, decisions, open questions and next dates.
An investor who needs to assess executive judgment benefits from a precise answer, not a performance of instant verbal fluency.
A useful phrase when a request is about the work rather than the diagnosis is: “For accurate due diligence, I prefer to send verified figures after the meeting rather than improvise numbers.” A founder should never use that phrase to evade information they owe. It is a commitment to greater accuracy.
For the founder who chooses to disclose, a similarly business-focused statement might be: “I am autistic. Written agendas help me prepare more substantive answers, and our team uses documented decisions so nothing depends on reading between the lines.”
Neither statement promises that the investor will respond well. Both shift attention from personality mythology to the quality of decision-making.
If an Investor Asks Directly About ADHD or Autism
A direct medical question in a fundraising meeting deserves more care than an impulsive yes or no.
Begin by identifying what problem the investor is trying to assess. Do they want assurance about succession, decision-making, time commitment, key-person risk or an operational dependency? You can invite them to articulate the business concern and answer it with relevant evidence.
For instance: “Could you tell me which operational risk you're evaluating? I can explain our leadership responsibilities, reporting and continuity arrangements.” That answer maintains boundaries without making false representations.
If the question appears discriminatory, intrusive or tied to an unusual contractual demand, pause before giving a binding representation. Consider documenting the exchange and consulting counsel, especially when term sheets, warranties or future board rights are involved. Legal protection will depend on the facts; no generic script can determine the result.
It is also reasonable to decide that an investor who insists on unnecessary medical details is not a good long-term partner. But founders facing scarce funding may have limited choices. Advice that assumes everyone can simply walk away ignores the unequal distribution of bargaining power.
Replace Founder Stereotypes With Due Diligence
Investors often say they fund people, not merely products. Fair enough. But what are they actually measuring when they decide a founder has “presence,” “grit,” or “founder DNA”?
If that judgment depends on conversational speed, unbroken eye contact, effortless networking, or similarity to prior successful founders, it risks confusing one cultural style of leadership with competence. These signals are attractive because they are quick. They are weak when used as substitutes for evidence.
A more serious assessment asks whether the founder understands the customer, makes decisions from data, learns from failure, recruits complementary talent, preserves trust, and can sustain execution over time. These questions matter for every founder, neurodivergent or not.
Investors should make questions specific, allow accessible meeting formats, and assess the quality of the answers rather than their presentation style. They also should not romanticize neurodivergence. ADHD does not automatically cause entrepreneurial creativity; autism does not guarantee analytical brilliance. Strengths, needs and context vary from person to person.
A Practical Decision Before the Next Investor Meeting
Before deciding what to share, a founder can privately work through five questions.
Purpose: What specific outcome would disclosure help produce—better communication, a values-aligned partnership, product credibility, or relief from masking?
Necessity: Can I obtain that outcome by describing a working preference or showing a business system without revealing medical information?
Trust: What do I know about this investor's conduct, confidentiality practices, diligence process and likely future role?
Risk: What might happen if the information is misunderstood, retained, forwarded or discussed outside this meeting?
Accuracy: Are there company risks or contractual representations that require frank discussion irrespective of my choice about personal disclosure?
The answers may change from a first introduction to a term-sheet negotiation and from one investor to another. A thoughtful choice is not less authentic because it is contextual.
Two Books, Two Ways to Think About the Question
Learning Coach's own publishing catalogue offers two complementary lenses. Neurodivergent Builders addresses masking, identity, energy, self-advocacy and the construction of systems around different ways of thinking. Its public description presents a journey from shame and self-understanding toward sustainable work and contribution. That makes it relevant to the personal cost of treating disclosure as a permanent performance decision.
The Hyperactive Founder focuses more directly on founder-brain fit, role design, team complementarity, money, decision discipline and investor translation. It speaks to the organizational dimension of the same problem: a company must make trust and execution visible through its operating architecture.
Both are Learning Coach Editions titles; this publication is part of Learning Coach. These connections are based on the publicly available publisher descriptions, not a claim of independent full-text literary review. Neither book replaces qualified legal advice, and neither should be mistaken for scientific proof that a diagnosis predicts entrepreneurial outcomes.
The most fruitful bridge between them is this: understand the mind privately or publicly as you choose; make the company's reliability observable.
The Right to Be Private—and the Responsibility to Be Clear
An investor does not need to be invited into every room of a founder's life. The company, however, must be intelligible to the people asked to finance it. Those are different obligations.
There will be founders for whom naming ADHD or autism opens a generous partnership. There will be others for whom retaining privacy is protective, rational and deeply considered. There will also be difficult cases where business facts, legal representations and personal information overlap, requiring individualized legal advice.
The most damaging rule would be a universal one: every neurodivergent founder must disclose, or none should.
A more demanding standard is possible. Let the founder decide what personal story to tell. Let the investor test the venture with evidence rather than stereotypes. And let the seriousness of the company be demonstrated not by how convincingly its founder resembles a familiar image of success, but by how responsibly its people build, govern and deliver.
You do not owe investors a diagnosis as a pitch. You do owe them an accurate account of the business.
Sources and Further Reading
The Entrepreneurs Network, Neurodiverse Founders (2024) — survey of 502 diagnosed UK founders; limitations noted above.
Howe, L. C., & Menges, J. I., Pitch Imperfect: How Investors Respond to Entrepreneur Disclosure of Personal Flaws (2025) — entrepreneurial disclosure research; not ADHD/autism-specific.
US Securities and Exchange Commission, Frequently Asked Questions About Exempt Offerings — antifraud responsibilities.
US Equal Employment Opportunity Commission, The ADA: Your Employment Rights as an Individual With a Disability — employment protections, not a blanket rule for equity investors.
Candice Matthews Brackeen, Raising Capital, Differently (2025) — investor-founder perspective.
No founders, investors, incidents or quotations were invented as factual case studies. The opening scenario and suggested phrases are illustrative.
